Compare NUS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | CADL |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 357.4M |
| IPO Year | 1996 | 2021 |
| Metric | NUS | CADL |
|---|---|---|
| Price | $7.27 | $4.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.71 |
| AVG Volume (30 Days) | 462.3K | ★ 1.2M |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ 207.80 | 58.62 |
| EPS | ★ 3.18 | N/A |
| Revenue | ★ $3,176,718,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $2.25 | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $5.32 | $4.25 |
| 52 Week High | $14.62 | $7.24 |
| Indicator | NUS | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 47.72 |
| Support Level | $7.02 | $4.58 |
| Resistance Level | $10.90 | $5.42 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 67.39 | 61.42 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.